Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Heather M. Rozjabek"'
Autor:
Carol Jamieson, Vanina Popova, Ella Daly, Kimberly Cooper, Wayne C. Drevets, Heather M. Rozjabek, Jaskaran Singh
Publikováno v:
Health and Quality of Life Outcomes, Vol 21, Iss 1, Pp 1-9 (2023)
Abstract Background Patients with treatment-resistant depression (TRD) report significant deficits in physical and mental health, as well as severely impaired health-related quality of life (HRQoL) and functioning. Esketamine effectively enhances the
Externí odkaz:
https://doaj.org/article/76775bc74595406289894ff630efa09e
Autor:
Heather M. Rozjabek, Ilana F. Gareen, Anthony B. Miller, Kathy L. Clingan, Pamela M. Marcus, Vincent P. Doria-Rose, JoRean D. Sicks, Brenda K. Brewer, Kristen Keating, Jennifer Rosenbaum, Joshua M. Rathmell
Publikováno v:
Clinical Trials. 13:434-438
Background/aims: Randomized controlled trials frequently use death review committees to assign a cause of death rather than relying on cause of death information from death certificates. The National Lung Screening Trial, a randomized controlled tria
Autor:
James N. Burroughs, Marie Topor, Erin E. Kent, Heather M. Rozjabek, Kimberly DeMichele, Rochelle L. Malinoff, Steven B. Clauser, Gigi Yuan, Anne B. Rodgers, Anita Ambs
Publikováno v:
Journal of the American Geriatrics Society. 64:186-192
Researchers and clinicians are increasingly recognizing the value of patient-reported outcome (PRO) data to better characterize people's health and experiences with illness and care. Considering the rising prevalence of cancer in adults aged 65 and o
Autor:
Philip C. Prorok, Josh Rathmell, Amanda Black, Heather M. Rozjabek, Thomas Riley, Pamela M. Marcus, Joe Austin, Jerome Mabie, Michael H. Young, Kelly J. Yu, Craig Williams
Publikováno v:
Reviews on Recent Clinical Trials. 10:233-237
The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial was a large, randomized controlled trial of cancer screening that also evolved over time into a unique epidemiologic cohort. Vast quantities of data have been collected since th
Autor:
Pamela M. Marcus, Heather M. Rozjabek, Thomas Riley, Shannon M. Pretzel, Lois Lamerato, Jeffery Childs, Brett Thomas, Lisa H. Gren, Jerome Mabie, Sheryl L. Ogden, Kayo Walsh
Publikováno v:
Preventive Medicine. 67:82-88
Identify predictors of non-compliance with first round screening exams in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.The PLCO was conducted from 1993 to 2011 at 10 US institutions. A total of 154,897 healthy men and wome
Autor:
Emily C. Dowling, Heather M. Rozjabek, Timothy S. McNeel, Gery P. Guy, Donatus U. Ekwueme, K. Robin Yabroff, Chunyu Li, Katherine S. Virgo
Publikováno v:
Medical Care. 52:594-601
BACKGROUND Although patient time costs are recommended for inclusion in cost-effectiveness analyses, these data are not routinely collected. We used nationally representative data and a medical service-based approach to estimate the annual patient ti
Autor:
K. Robin Yabroff, Donatus U. Ekwueme, Laura P. Forsythe, Heather M. Rozjabek, Janet S. de Moor, Neetu Chawla, Timothy S. McNeel, Emily C. Dowling
Publikováno v:
Cancer. 119:3393-3401
BACKGROUND Cancer survivors may experience long-term and late effects from treatment that adversely affect health and limit functioning. Few studies examine lost productivity and disease burden in cancer survivors compared with individuals who have o
Autor:
Shannon M. Pretzel, Heather M. Rozjabek, Karen Broski, Brett Thomas, Jeffery Childs, Lisa H. Gren, Jerome Mabie, Sheryl L. Ogden, Pamela M. Marcus, Tara S. Andrews
Publikováno v:
Clinical medicineresearch. 13(3-4)
The ability of clinical trials to rigorously examine research questions depends on many factors. Careful adherence to clinical aspects of the protocol is of the utmost importance, yet a trial cannot be successful unless participants actually particip
Autor:
Julietta Patnick, Carrie N. Klabunde, Heather M. Rozjabek, Sven Törnberg, Verna Mai, Carlo Senore, Lea Hagoel, Johannes Blom, Montse Garcia, Jean-Luc Bulliard
Publikováno v:
Journal of medical screening. 22(3)
Objective Participation, an indicator of screening programme acceptance and effectiveness, varies widely in clinical trials and population-based colorectal cancer (CRC) screening programmes. We aimed to assess whether CRC screening participation rate
Autor:
Steven R. Machlin, Emily C. Dowling, Donatus U. Ekwueme, Katherine S. Virgo, Heather M. Rozjabek, Timothy S. McNeel, Pamela Farley Short, Chunyu Li, K. Robin Yabroff
Background Access to health care, particularly effective primary and secondary preventive care, is critical for cancer survivors, in order to minimize the adverse sequelae of cancer and its treatment. Purpose The goal of the study was to evaluate the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::520cc2750a4c4f6388a163919ad2f174
https://europepmc.org/articles/PMC3804250/
https://europepmc.org/articles/PMC3804250/